# Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

> **NCT02285413** · PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 54 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** DC vaccination
- **BIOLOGICAL:** DC vaccination with cisplatinum

## Key facts

- **NCT ID:** NCT02285413
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2015-10
- **Final completion:** 2016-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02285413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02285413, "Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02285413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*